Benoist Chibaudel

Levallois-perret, 92300, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 103 publications

Diagnostic Challenges of Tumor Tissue and Circulating Microsatellite Status Assessment in Metastatic Colorectal Cancer and Their Impact on Access to Immunotherapy: A Real-World Retrospective Study.

Diagnostic Challenges of Tumor Tissue and Circulating Microsatellite Status Assessment in Metastatic Colorectal Cancer and Their Impact on Access to Immunotherapy: A Real-World Retrospective Study.

Journal: Cancers
Published: May 14, 2026

Evaluating longitudinal toxicity and adverse event in cetuximab-treated metastatic colorectal cancer: a pooled analysis from 1,302 patients in ARCAD database.

Evaluating longitudinal toxicity and adverse event in cetuximab-treated metastatic colorectal cancer: a pooled analysis from 1,302 patients in ARCAD database.

Journal: Journal of the National Cancer Institute
Published: April 28, 2026

Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial.

Impact of nutritional risk screening on outcomes of first-line treatment in metastatic esophagogastric adenocarcinoma: a secondary analysis of the AIO-MATEO trial.

Journal: ESMO gastrointestinal oncology
Published: April 17, 2026

Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.

Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.

Journal: Journal of the National Cancer Institute
Published: April 14, 2026

Prognostic Impact of Blood Tumor Mutational Burden in pMMR/MSS Metastatic Colorectal Cancer Assessed by FoundationOne® Liquid CDx.

Prognostic Impact of Blood Tumor Mutational Burden in pMMR/MSS Metastatic Colorectal Cancer Assessed by FoundationOne® Liquid CDx.

Journal: Cancers
Published: January 05, 2026

Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database.

Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC Database.

Journal: Clinical colorectal cancer
Published: November 03, 2025

Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 - PRODIGE 84 phase II trial (PREMICES).

Neoadjuvant pembrolizumab with a watch‑and‑wait strategy for localized MSI/dMMR colon cancer: Study protocol for a randomized GERCOR 109 - PRODIGE 84 phase II trial (PREMICES).

Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: October 31, 2025

Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.

Quantitative ctDNA Profiling of RAS Mutations as a Prognostic Biomarker in Metastatic Colorectal Cancer.

Journal: International journal of molecular sciences
Published: October 10, 2025

Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.

Ezabenlimab and induction chemotherapy followed by adaptive chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma (INTERACT-ION): an open-label, single-arm, phase 2 trial.

Journal: The Lancet. Oncology
Published: August 08, 2025

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.

Characteristics of Patients and Prognostic Factors Across Treatment Lines in Metastatic Colorectal Cancer: An Analysis From the Aide et Recherche en Cancérologie Digestive Database.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 05, 2025

Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study.

Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study.

Journal: Journal for immunotherapy of cancer
Published: April 14, 2025

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.

Journal: Signal transduction and targeted therapy
Published: March 05, 2025
Showing 1-12 of 103

Last Updated: 09/26/2026